Short Interest in Azitra, Inc. (NYSEAMERICAN:AZTR) Expands By 112.1%

Azitra, Inc. (NYSEAMERICAN:AZTR) saw a large growth in short interest in January. As of January 30th, there was short interest totaling 382,396 shares, a growth of 112.1% from the January 15th total of 180,273 shares. Based on an average daily trading volume, of 1,657,213 shares, the short-interest ratio is currently 0.2 days. Currently, 3.6% of the shares of the stock are short sold. Currently, 3.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,657,213 shares, the short-interest ratio is currently 0.2 days.

Azitra Price Performance

Shares of NYSEAMERICAN AZTR opened at $0.20 on Friday. Azitra has a 12 month low of $0.19 and a 12 month high of $2.97. The stock has a 50-day moving average price of $0.28 and a two-hundred day moving average price of $0.56.

Azitra (NYSEAMERICAN:AZTR) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.12. Equities analysts forecast that Azitra will post -2.78 earnings per share for the current fiscal year.

Azitra Company Profile

Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.

The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.